| 000 | 01545 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517020330.0 | ||
| 264 | 0 | _c20151104 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1468-1293 | ||
| 024 | 7 |
_a10.1111/hiv.12231 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharma, S | |
| 245 | 0 | 0 |
_aDemographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. _h[electronic resource] |
| 260 |
_bHIV medicine _cApr 2015 |
||
| 300 |
_a30-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Retroviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xmethods |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDemography |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBabiker, A G | |
| 700 | 1 | _aEmery, S | |
| 700 | 1 | _aGordin, F M | |
| 700 | 1 | _aLundgren, J D | |
| 700 | 1 | _aNeaton, J N | |
| 700 | 1 | _aBakowska, E | |
| 700 | 1 | _aSchechter, M | |
| 700 | 1 | _aWiselka, M J | |
| 700 | 1 | _aWolff, M J | |
| 773 | 0 |
_tHIV medicine _gvol. 16 Suppl 1 _gp. 30-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/hiv.12231 _zAvailable from publisher's website |
| 999 |
_c24651810 _d24651810 |
||